Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initiation of agomelatine after SSRI/SNRI treatment in major depressive disorder
2010-019556-44Phase 3Completed
- Sponsor
- Servier
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of agomelatine in major depressive disorder (MDD) (3 arms), sponsored by Servier. Primary endpoint: Total number of discontinuation-emergent symptoms. Started Jun 2010; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-019556-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019556-44.